These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25169961)

  • 1. Addressing current treatment challenges in Crohn's disease in real life: a physician's survey.
    Vavricka SR; Radivojevic S; Manser CN; Frei P; Burri E; Fried M; Schoepfer A; Peyrin-Biroulet L; Michetti P; Rogler G; Biedermann L
    Dig Liver Dis; 2014 Dec; 46(12):1066-71. PubMed ID: 25169961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
    Ong DE; Kamm MA; Hartono JL; Lust M
    J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.
    Russo EA; Iacucci M; Lindsay JO; Campbell S; Hart A; Hamlin J; Orchard T; Arebi N; Nightingale J; Jacyna MR; Gabe SM; O'Connor M; Harris AW; O'Morain C; Ghosh S
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):334-9. PubMed ID: 19528808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists.
    Duchesne C; Faure P; Kohler F; Pingannaud MP; Bonnaud G; Devulder F; Abramowitz L; Boustière C; Peyrin-Biroulet L;
    Dig Liver Dis; 2014 Aug; 46(8):675-81. PubMed ID: 24809234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF antagonists in the treatment of inflammatory bowel disease: results of a survey of gastroenterologists in the French region of Lorraine.
    Peyrin-Biroulet L; Oussalah A; Boucekkine T; Bigard MA
    Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):23-30. PubMed ID: 19118965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How thiopurines are used for the treatment of inflammatory bowel diseases: an Italian survey.
    Saibeni S; Kohn A; Meucci G; Papi C;
    Dig Liver Dis; 2015 Feb; 47(2):170-3. PubMed ID: 25467827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
    Leung Y; Hanauer SB
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S202-8. PubMed ID: 20117343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing changes in clinical practice to improve the management of Crohn's disease.
    Panaccione R; Hibi T; Peyrin-Biroulet L; Schreiber S
    J Crohns Colitis; 2012 Feb; 6 Suppl 2():S235-42. PubMed ID: 22463930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.
    Oussalah A; Roblin X; Laharie D; Filippi J; Flamant M; Faure P; Phelip JM; Bigard MA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(8):854-63. PubMed ID: 19764940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid?
    Fascì Spurio F; Aratari A; Margagnoni G; Doddato MT; Papi C
    J Gastrointestin Liver Dis; 2012 Mar; 21(1):67-73. PubMed ID: 22457862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
    Ng SC; Plamondon S; Gupta A; Burling D; Swatton A; Vaizey CJ; Kamm MA
    Am J Gastroenterol; 2009 Dec; 104(12):2973-86. PubMed ID: 19755971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
    Hinojosa J; Gisbert JP; Gomollón F; López San Román A
    J Crohns Colitis; 2012 Aug; 6(7):763-70. PubMed ID: 22398092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical management of Crohn's disease.
    Cottone M; Renna S; Orlando A; Mocciaro F
    Expert Opin Pharmacother; 2011 Nov; 12(16):2505-25. PubMed ID: 21988215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease.
    Srinivasan A; Vasudevan A; McFarlane A; Sparrow MP; Gibson PR; Van Langenberg DR
    J Crohns Colitis; 2018 Feb; 12(3):280-288. PubMed ID: 29077839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
    Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.